🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Azadeh Namakydoust

Merck & Co., Inc., Rahway, NJ, USA (United States)

ORCID: 0000-0002-5252-5648
Biochemistry, Genetics and Molecular BiologyMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

0in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 7 papers. Top paper: Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 study.

N/A
0.840DataRank · unranked
270 citations

Hira Rizvi, Isabel R. Preeshagul, Jacklynn V. Egger, David Hoyos, Chai Bandlamudi +26 more

195 citations

Emily S. Lebow, Randy Yeh, Jeeban Paul Das, Azadeh Namakydoust, Paul K. Paik +67 more

N/A
0DataRank · unranked
4 citations

Elena N. Petre, Ken Zhao, Vlasios S. Sotirchos, Azadeh Namakydoust, Amgad M. Moussa +5 more

37 citations

Pang‐Dian Fan, Besnik Qeriqi, Azadeh Namakydoust, Bobby Daly, Linda S. Ahn +9 more

19 citations

Emily S. Lebow, Yonina R. Murciano‐Goroff, Gowtham Jayakumaran, Ronglai Shen, A. Rose Brannon +15 more

6 citations

Prasad S. Adusumilli, Michael Offin, Stephen B. Solomon, Etay Ziv, Sara A. Hayes +22 more